Interestingly, miR-31 regulates inflammation in RA by targeting TLR4 and reducing pro-inflammatory markers like TNF-α and IL-1, while promoting apoptosis in synovial cells, positioning it as a potential therapeutic target for RA (93). This evidence concerns the gene IL1B and rheumatoid arthritis.